Circulating Tumor Cell Clinical Trials

7 recruiting

Circulating Tumor Cell Trials at a Glance

9 actively recruiting trials for circulating tumor cell are listed on ClinicalTrialsFinder across 6 cities in 7 countries. The largest study group is Not Applicable with 4 trials, with the heaviest enrollment activity in Guangzhou, Hong Kong, and Linz. Lead sponsors running circulating tumor cell studies include Chang Gung Memorial Hospital, Chinese University of Hong Kong, and AC Camargo Cancer Center.

Browse circulating tumor cell trials by phase

Treatments under study

About Circulating Tumor Cell Clinical Trials

Looking for clinical trials for Circulating Tumor Cell? There are currently 7 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Circulating Tumor Cell trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Circulating Tumor Cell clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 19 of 9 trials

Recruiting
Not Applicable

CTCs in Breast Cancer After Neoadjuvant Treatment and Surgery: a Multicenter, Prospective Clinical Trial

Breast CancerCirculating Tumor Cell
RenJi Hospital484 enrolled1 locationNCT05360290
Recruiting

Predicting Clinical Efficacy of Immunotherapy Using Pre-treatment andContinuousMonitoring of PD-L1 TPS/CPS on CTCs, and Immunity Exhaustion Scores

ImmunotherapyCirculating Tumor Cells (CTCs)PD-L1 Expression+1 more
Chang Gung Memorial Hospital150 enrolled1 locationNCT07396259
Recruiting
Not Applicable

Liquid Biopsy and Pancreas Cancer: Detection of AXL(+) CTCs (CTC-AXL-PANC)

Metastatic Pancreatic CancerPancreatic Ductal AdenocarcinomaCirculating Tumor Cell
University Hospital, Montpellier63 enrolled1 locationNCT05346536
Recruiting
Not Applicable

In Vivo Liquid Biopsy of Melanoma (Cytophone)

MelanomaMetastatic MelanomaDiagnosis+1 more
Cytoastra180 enrolled1 locationNCT06488365
Recruiting

Detecting Chemosensitivity and Predicting Treatmemt Efficacy With CTCs in mNPC

Circulating Tumor CellNasopharyngeal CarcinomaEffects of Chemotherapy+1 more
Sun Yat-sen University50 enrolled1 locationNCT04544969
Recruiting

Using a 3D Culture Model for Circulating Tumor Cells Combined With Molecular Bioassays in Patients With HNSCC Cancer

HNSCCCirculating Tumor Cell
Chang Gung Memorial Hospital88 enrolled1 locationNCT06755762
Recruiting
Phase 3

Liquid Biopsy (ctDNA) Guided Treatment in Localized Pancreatic Cancer: Neoadjuvant CTX vs. Upfront Surgery

Pancreatic CancerCirculating Tumor CellPredictive Cancer Model
Elisabethinen Hospital100 enrolled1 locationNCT06391892
Recruiting
Phase 2

Circulating Tumor Cells and Treatment De-escalation After Neoadjuvant Therapy for HER2 Positive Breast Cancer

Breast NeoplasmsHER2-positive Breast CancerCirculating Tumor Cell
AC Camargo Cancer Center80 enrolled1 locationNCT04993014
Recruiting
Not Applicable

EUS Guided HVA and PVA for Circulating Tumor DNA in Patients

Circulating Tumor CellGastrointestinal Cancer
Chinese University of Hong Kong60 enrolled1 locationNCT04782557